ArticleJournal of virology1996
Antiviral cytotoxic T-cell memory by vaccination with recombinant Listeria monocytogenes.
Article in Journal of virology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Clinical Response of Live-Attenuated,Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.Frontiers in cellular and infection microbiology · 2014Review
- Disparate roles for STAT5 in primary and secondary CTL responses.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Characterization of CD8+ T cell function and immunodominance generated with an H2O2-inactivated whole-virus vaccine.Journal of virology · 2012Article
- Stability and function of secondary Th1 memory cells are dependent on the nature of the secondary stimulus.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Development of a new hydrogen peroxide–based vaccine platform.Nature medicine · 2012Article
- A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- The magnitude of CD4+ T cell recall responses is controlled by the duration of the secondary stimulus.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Induction of long-term protective immune responses by influenza H5N1 virus-like particles.PloS one · 2009Article
- Selected prfA* mutations in recombinant attenuated Listeria monocytogenes strains augment expression of foreign immunogens and enhance vaccine-elicited humoral and cellular immune responses.Infection and immunity · 2008Article
- Measles virus infection results in suppression of both innate and adaptive immune responses to secondary bacterial infection.The Journal of clinical investigation · 2003Article
- Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation.Infection and immunity · 2002Article
- A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA.Journal of virology · 1997Article
- Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.Proceedings of the National Academy of Sciences of the United States of America · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Listeria monocytogenes is a facultative intracellular bacterium that is able to escape phagocytic vesicles and replicate in the cytoplasm of infected cells. As with viral vectors, this intracytoplasmic life cycle provides a means for introducing foreign proteins into the major histocompatibility complex class I pathway of antigen presentation. Using recombinant L. monocytogenes (rLM) strains expressing the full-length nucleoprotein (NP) or a single cytotoxic T-lymphocyte (CTL) epitope from lymphocytic choriomeningitis virus (LCMV), we analyzed antiviral CTL responses induced by rLM vaccination. After vaccination, rLM was cleared from the host within 7 days while inducing an LCMV-specific ex vivo CD8+ effector CTL response. Virus-specific CTL memory was maintained for 6 months postvaccination, as demonstrated by vigorous secondary CTL responses after in vitro stimulation. A single immunization with rLM that expressed either the full-length NP gene or the CTL epitope alone resulted in LCMV NP-specific CTL precursor frequencies of approximately 1/10(4) CD8+ T cells. A second rLM vaccination resulted in enhanced virus-specific CTL activity and in vitro proliferation. rLM-vaccinated mice were protected against chronic viral infection by an accelerated virus-specific memory CTL response. These mice cleared infectious virus as well as viral antigen, suggesting that sterilizing immunity was achieved. In contrast to mice that received wild-type LM, rLM-vaccinated mice were protected from virally induced immunosuppression and splenic atrophy associated with chronic LCMV infection. The ability to elicit long-term cell-mediated immunity is fundamental in designing vaccines against intracellular pathogens, and these results demonstrate the efficacy of recombinant LM vaccination for inducing protective antiviral CTL memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.